Magnasense Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Marco Wititteveen

Chief executive officer

SEK 2.4m

Total compensation

CEO salary percentage	47.2%
CEO tenure	1.4yrs
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

CEO Compensation Analysis

How has Marco Wititteveen's remuneration changed compared to Magnasense's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-SEK 41m
Mar 31 2024	n/a	n/a	-SEK 49m
Dec 31 2023	SEK 2m	SEK 1m	-SEK 60m

Compensation vs Market: Marco's total compensation ($USD225.22K) is about average for companies of similar size in the Swedish market ($USD244.41K).

Compensation vs Earnings: Insufficient data to compare Marco's compensation with company performance.

CEO

Marco Wititteveen (55 yo)

1.4yrs

Tenure

SEK 2,420,854

Compensation

Mr. Marco Wititteveen serves as Chief Executive Officer of Magnasense AB (formerly known as AegirBio AB (publ)) since June 15, 2023 and serves as its Member of the Board. He has previously had multiple dif...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Marco Wititteveen	CEO & Member of the Board	1.4yrs	SEK 2.42m	no data
Vicki Johnson	Interim Chief Financial Officer	less than a year	no data	no data
Vasiliki Fragkou	Chief Operating Officer	less than a year	no data	no data

1.0yrs

Average Tenure

Experienced Management: MAGNA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Marco Wititteveen	CEO & Member of the Board	no data	SEK 2.42m	no data
William Ferenczy	Member of the Board	less than a year	no data	no data
William Vickery	Independent Director	2.8yrs	SEK 105.00k	no data
Michael Schwartz	Member of the Board	less than a year	no data	no data
Iain L. Chapple	Member of Scientific Advisory Board	less than a year	no data	no data
Fredrik Haglund	Independent Member of the Board	4.5yrs	SEK 105.00k	0.38% SEK 31.2k
Jens Umehag	Chairman	no data	no data	no data
Adam Cheifetz	Scientific Advisory Board	less than a year	no data	no data
Melissa Grant	Member of Scientific Advisory Board	less than a year	no data	no data

0.8yrs

Average Tenure

54.5yo

Average Age

Experienced Board: MAGNA's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Magnasense Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Magnasense AB Announces Chief Financial Officer Changes

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

Recent updates

New major risk - Shareholder dilution

Magnasense AB Announces Filing of A Patent Application Covering an Advanced Detection System Designed to Improve the Sensitivity and Accuracy of Magnetic Test Strips Using Superparamagnetic Nanoparticles

Less than half of directors are independent

First half 2024 earnings released: kr0.42 loss per share (vs kr1.36 loss in 1H 2023)

Magnasense AB Announces Chief Financial Officer Changes

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: kr0.16 loss per share (vs kr0.64 loss in 1Q 2023)

New minor risk - Share price stability

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr2.38 loss per share (vs kr18.90 loss in FY 2022)

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

New minor risk - Share price stability

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Aegirbio AB Receives Phase 1 Award from the National Institutes of Health (Nih) Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing

AegirBio Announces Management Changes

Aegirbio AB (Publ) Announces CEO Changes

Independent Member of the Board exercised options to buy kr86k worth of stock.

AegirBio AB (publ) announced that it expects to receive SEK 55 million in funding from Atlas Special Opportunities LLC

High number of new and inexperienced directors

AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covid-19 Antigen Test

AegirBio Announces First Clinical Saliva TDM Study in US

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio AB (publ) Receives Intention to Grant from the European Patent Office

New 90-day high: kr30.88

Aegirbio Announces the Addition of Brandon Steele to Their Senior Management Team as Chief Commercial Officer

AegirBio AB (publ) (OM:AEGIR) agreed to acquire LifeAssays AB (publ) (NGM:LIFE B)

New 90-day high: kr25.50

AegirBio AB (publ) Announces That the Direct Aid of Approximately SEK 4.3 Million or €419,500 Granted to Aegirbio AB’s Eurostar application

Aegirbio Commences FDA Fast Track Process with COVID-19 Test

Aegirbio Announces Convincing Results for Aegirbio's Coronavirus Test in Italian-Swedish Study

Aegirbio AB Signs A Research & Development Agreement with MediaPharma

AegirBio AB (publ) (OM:AEGIR) acquired Viraspec AB for SEK 10 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age